At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,157 enrolled
Drug / intervention
t:slim X2 pump with Control-IQ technologydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Control-IQ Observational (CLIO) Post-Approval Study
In Brief
An observational study evaluating t:slim X2 pump with Control-IQ technology for Diabetes Mellitus, Type 1. Completed, enrolled 3,157 participants across 1 site.
Detailed Summary
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
CollaboratorsUniversity of California, San Diego
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedAug 2020
Primary CompletionJun 2023
Study CompletionJun 2023
TodayJul 2026
First PostedAug 7, 2020
Enrollment StartAug 4, 2020
Primary CompletionJun 2, 2023
Study CompletionJun 26, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.9 years ago
Interventions
t:slim X2 pump with Control-IQ technologydevice
Real-world use